Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations

Biochemistry

Volumn 45, Issue 23, 2006, Pages 7334-7340

  Basavapathruni, Aravind ^a   Vingerhoets, Johan ^b   De Béthune, Marie Pierre ^b   Chung, Raymond ^a   Bailey, Christopher M ^a   Kim, Jiae ^a   Anderson, Karen S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Tibotec   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINETRIPHOSPHATE; BIOCHEMISTRY; CELL CULTURE; PHOSPHATES; VIRUSES;

CHAIN TERMINATION; HIV INHIBITION; MUTATIONS; REVERSE TRANSCRIPTASE (RT); SYNERGY;

ENZYME INHIBITION;

ADENOSINE TRIPHOSPHATE; ANTIRETROVIRUS AGENT; ASPARAGINE; CYSTEINE; EFAVIRENZ; ETRAVIRINE; LYSINE; MUTANT PROTEIN; NEVIRAPINE; PRIMER DNA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TYROSINE; ZIDOVUDINE 5' PHOSPHATE; ZIDOVUDINE 5' TRIPHOSPHATE;

AMINO ACID SUBSTITUTION; ARTICLE; CELL CULTURE; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MODULATION; MUTATION; NONHUMAN; PRIORITY JOURNAL; SYNERGISTIC INHIBITION; VIRUS INHIBITION; VIRUS REPLICATION;

BASE SEQUENCE; DNA PRIMERS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33745032037     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi052362v     Document Type: Article

References (56)

1. Hammer, S. M., Kassler, H. A., and Saag, M. S. (1994) Issues in combination antiretroviral therapy: a review, JAIDS, J. Acquired Immune Defic. Syndr. 7 (Suppl. 2), S24-S35; discussion S35-S37.
2. De Clercq, E. (1992) HIV inhibitors targeted at the reverse transcriptase, AIDS Res. Hum. Retroviruses 8, 119-134.
3. Goody, R. S., Muller, B., and Restle, T. (1991) Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo, FEBS Lett. 291, 1-5.
4. Tantillo, C., Ding, J., Jacobo-Molina, A., Nanni, R. G., Boyer, P. L., Hughes, S. H., Pauwels, R., Andries, K., Janssen, P. A., and Arnold, E. (1994) Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance, J. Mol. Biol. 243, 369-387.
5. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., and Steitz, T. A. (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor, Science 256, 1783-1790.
6. Spence, R. A., Kati, W. M., Anderson, K. S., and Johnson, K. A. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors, Science 267, 988-993.
7. Rittinger, K., Divita, G., and Goody, R. S. (1995) Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors, Proc. Natl. Acad. Sci. U.S.A. 92, 8046-8049.
8. Loeb, L. A., Essigmann, J. M., Kazazi, F., Zhang, J., Rose, K. D., and Mullins, J. I. (1999) Lethal mutagenesis of HIV with mutagenic nucleoside analogues, Proc. Natl. Acad. Sci. U.S.A. 96, 1492-1497.
9. Vaccaro, J. A., Parnell, K. M., Terezakis, S. A., and Anderson, K. S. (2000) Mechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP: an equivalent incorporation efficiency relative to the natural substrate dTTP, Antimicrob. Agents Chemother. 44, 217-221.
10. Vaccaro, J. A., and Anderson, K. S. (1998) Implication of the tRNA initiation step for human immunodeficiency virus type 1 reverse transcriptase in the mechanism of 3′-azido-3′-deoxythymidine (AZT) resistance, Biochemistry 37, 14189-14194.
11. Ray, A. S., and Anderson, K. S. (2001) Mechanistic studies to understand the inhibition of wild type and mutant HIV-1 reverse transcriptase by Carbovir-triphosphate, Nucleosides, Nucleotides Nucleic Acids 20, 1247-1250.
12. Ray, A. S., Yang, Z., Shi, J., Hobbs, A., Schinazi, R. F., Chu, C. K., and Anderson, K. S. (2002) Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate, Biochemistry 41, 5150-5162.
13. Feng, J. Y., and Anderson, K. S. (1999) Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase, Biochemistry 38, 9440-9448.
14. Ray, A. S., Schinazi, R. F., Murakami, E., Basavapathruni, A., Shi, J., Zorca, S. M., Chu, C. K., and Anderson, K. S. (2003) Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase, Antiviral Chem. Chemother. 14, 115-125.
15. Meyer, P. R., Matsuura, S. E., Tolun, A. A., Pfeifer, I., So, A. G., Mellors, J. W., and Scott, W. A. (2002) Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents Chemother. 46, 1540-1545.
16. Meyer, P. R., Matsuura, S. E., Schinazi, R. F., So, A. G., and Scott, W. A. (2000) Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates, Antimicrob. Agents Chemother. 44, 3465-3472.
17. Meyer, P. R., Matsuura, S. E., Mian, A. M., So, A. G., and Scott, W. A. (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase, Mol. Cell 4, 35-43.
18. Meyer, P. R., Matsuura, S. E., So, A. G., and Scott, W. A. (1998) Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism, Proc. Natl. Acad. Sci. U.S.A. 95, 13471-13476.
19. Ray, A. S., Murakami, E., Basavapathruni, A., Vaccaro, J. A., Ulrich, D., Chu, C. K., Schinazi, R. F., and Anderson, K. S. (2003) Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis, Biochemistry 42, 8831-8841.
20. Basavapathruni, A., Bailey, C. M., and Anderson, K. S. (2004) Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs, J. Biol. Chem. 279, 6221-6224.
21. Spence, R. A., Anderson, K. S., and Johnson, K. A. (1996) HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors, Biochemistry 35, 1054-1063.
22. Schinazi, R. F., Larder, B. A., and Mellors, J. W. (1997) Mutations in retroviral genes associated with drug resistance, Int. Antiviral News 5, 129-135.
23. Ren, J., Milton, J., Weaver, K. L., Short, S. A., Stuart, D. I., and Stammers, D. K. (2000) Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase, Struct. Folding Des. 8, 1089-1094.
24. Lindberg, J., Sigurdsson, S., Lowgren, S., Andersson, H. O., Sahlberg, C., Noreen, R., Fridborg, K., Zhang, H., and Unge, T. (2002) Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant, Eur. J. Biochem. 269, 1670-1677.
25. Domaoal, R. A., and Demeter, L. M. (2004) Structural and biochemical effects of human immunodeficiency virus mutants resistant to nonnucleoside reverse transcriptase inhibitors, Int. J. Biochem. Cell Biol. 36, 1735-1751.
26. King, R. W., Klabe, R. M., Reid, C. D., and Erickson-Viitanen, S. K. (2002) Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors, Antimicrob. Agents Chemother. 46, 1640-1646.
27. De Clercq, E. (1998) The role of nonnucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection, Antiviral Res. 38, 153-179.
28. Odriozola, L., Cruchaga, C., Andreola, M., Dolle, V., Nguyen, C. H., Tarrago-Litvak, L., Perez-Mediavilla, A., and Martinez-Irujo, J. J. (2003) Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase Inhibit Phosphorolysis and Resensitize the 3′-Azido-3′-deoxythymidine (AZT)-resistant Polymerase to AZT-5′-triphosphate, J. Biol. Chem. 278, 42710-42716.
29. Cruchaga, C., Odriozola, L., Andreola, M., Tarrago-Litvak, L., and Martinez-Irujo, J. J. (2005) Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3′-azido-3′-deoxythymidine with nonnucleoside inhibitors, Biochemistry 44, 3535-3546.
30. Borkow, G., Arion, D., Wainberg, M. A., and Parniak, M. A. (1999) The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1, Antimicrob. Agents Chemother. 43, 259-263.
31. Kerr, S. G., and Anderson, K. S. (1997) Pre-steady-state kinetic characterization of wild type and 3′-azido-3′-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance, Biochemistry 36, 14064-14070.
32. Johnson, A. A., Ray, A. S., Hanes, J., Suo, Z., Colacino, J. M., Anderson, K. S., and Johnson, K. A. (2001) Toxicity of antiviral nucleoside analogues and the human mitochondrial DNA polymerase, J. Biol. Chem. 276, 40847-40857.
33. Murakami, E., Feng, J. Y., Lee, H., Hanes, J., Johnson, K. A., and Anderson, K. S. (2003) Characterization of novel reverse transcriptase and other RNA-associatedpar catalytic activities by human DNA polymerase gamma: importance in mitochondrial DNA replication, J. Biol. Chem. 278, 36403-36409.
34. Zhu, Q. Y., Scarborough, A., Polsky, B., and Chou, T. C. (1996) Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains, AIDS Res. Hum. Retroviruses 12, 507-517.
35. Maga, G., Hubscher, U., Pregnolato, M., Ubiali, D., Gosselin, G., and Spadari, S. (2001) Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogues, Antimicrob. Agents Chemother. 45, 1192-1200.
36. Johnson, V. A., Brun-Vezinet, F., Clotet, B., Conway, B., D'Aquila, R. T., Demeter, L. M., Kuritzkes, D. R., Pillay, D., Schapiro, J. M., Telenti, A., and Richman, D. D. (2003) Drug resistance mutations in HIV-1, Top. HIV Med. 11, 215-221.
37. Delaugerre, C., Rohban, R., Simon, A., Mouroux, M., Tricot, C., Agher, R., Huraux, J. M., Katlama, C., and Calvez, V. (2001) Resistance profile and cross-resistance of HIV-1 among patients failing a nonnucleoside reverse transcriptase inhibitor-containing regimen, J. Med. Virol. 65, 445-448.
38. Selmi, B., Deval, J., Alvarez, K., Boretto, J., Sarfati, S., Guerreiro, C., and Canard, B. (2003) The Y181C substitution in 3′-azido-3′- deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3′-azido-3′- deoxythymidine 5′-monophosphate-terminated primer, J. Biol. Chem. 278, 40464-40472.
39. Meyer, P. R., Smith, A. J., Matsuura, S. E., and Scott, W. A. (2004) Effects of primer-template sequence on ATP-dependent removal of chain-terminating nucleotide analogues by HIV-1 reverse transcriptase, J. Biol. Chem. 279, 45389-45398.
40. Das, K., Clark, A. D., Jr., Lewi, P. J., Heeres, J., De Jonge, M. R., Koymans, L. M., Vinkers, H. M., Daeyaert, F., Ludovici, D. W., Kukla, M. J., De Corte, B., Kavash, R. W., Ho, C. Y., Ye, H., Lichtenstein, M. A., Andries, K., Pauwels, R., De Bethune, M. P., Boyer, P. L., Clark, P., Hughes, S. H., Janssen, P. A., and Arnold, E. (2004) Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants, J. Med. Chem. 47, 2550-2560.
41. Bacheler, L., Jeffrey, S., Hanna, G., D'Aquila, R., Wallace, L., Logue, K., Cordova, B., Hertogs, K., Larder, B., Buckery, R., Baker, D., Gallagher, K., Scarnati, H., Tritch, R., and Rizzo, C. (2001) Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy, J. Virol. 75, 4999-5008.
42. Young, S. D., Britcher, S. F., Tran, L. O., Payne, L. S., Lumma, W. C., Lyle, T. A., Huff, J. R., Anderson, P. S., Olsen, D. B., Carroll, S. S., et al. (1995) L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents Chemother. 39, 2602-2605.
43. Balzarini, J., De Clercq, E., Carbonez, A., Burt, V., and Kleim, J. P. (2000) Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors, AIDS Res. Hum. Retroviruses 16, 517-528.
44. De Clerc, Q. E. (2004) Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): past, present, and future, Chem. Biodiversity 1, 44-64.
45. Pauwels, R. (2004) New nonnucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections, Curr. Opin. Pharmacol. 4, 437-446.
46. Janssen, P. A., Lewi, P. J., Arnold, E., Daeyaert, F., de Jonge, M., Heeres, J., Koymans, L., Vinkers, M., Guillemont, J., Pasquier, E., Kukla, M., Ludovici, D., Andries, K., de Bethune, M. P., Pauwels, R., Das, K., Clark, A. D., Jr., Frenkel, Y. V., Hughes, S. H., Medaer, B., De Knaep, F., Bohets, H., De Clerck, F., Lampo, A., Williams, P., and Stoffels, P. (2005) In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile (R278474, rilpivirine), J. Med. Chem. 48, 1901-1909.
47. Ludovici, D. W., De Corte, B. L., Kukla, M. J., Ye, H., Ho, C. Y., Lichtenstein, M. A., Kavash, R. W., Andries, K., de Bethune, M. P., Azijn, H., Pauwels, R., Lewi, P. J., Heeres, J., Koymans, L. M., de Jonge, M. R., Van Aken, K. J., Daeyaert, F. F., Das, K., Arnold, E., and Janssen, P. A. (2001) Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues, Bioorg. Med. Chem. Lett. 11, 2235-2239.
48. Andries, K., Azijn, H., Thielemans, T., Ludovici, D., Kukla, M., Heeres, J., Janssen, P., De Corte, B., Vingerhoets, J., Pauwels, R., and de Bethune, M. P. (2004) TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1, Antimicrob. Agents Chemother. 48, 4680-4686.
49. Sankatsing, S. U., Weverling, G. J., Peeters, M., van't Klooster, G., Gruzdev, B., Rakhmanova, A., Danner, S. A., Jurriaans, S., Prins, J. M., and Lange, J. M. (2003) TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen, AIDS 17, 2623-2627.
50. Gruzdev, B., Rakhmanova, A., Doubovskaya, E., Yakovlev, A., Peeters, M., Rinehart, A., de Dier, K., Baede-Van Dijk, P., Parys, W., and van't Kloosler, G. (2003) A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infecled subjecls, AIDS 17, 2487-2494.
51. Gazzard, B. G., Pozniak, A. L., Rosenbaum, W., Yeni, G. P., Staszewski, S., Arasteh, K., De Dier, K., Peeters, M., Woodfall, B., Stebbing, J., and van't Klooster, G. A. (2003) An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resislance, AIDS 17, F49-F54.
52. Udier-Blagovic, M., Tirado-Rives, J., and Jorgensen, W. L. (2003) Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125, J. Am. Chem. Soc. 125, 6016-6017.
53. Vaccaro, J. A., Singh, H. A., and Anderson, K. S. (1999) Initiation of minus-strand DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase, Biochemistry 38, 15978-15985.
54. Crespan, E., Localelli, G. A., Cancio, R., Hubscher, U., Spadari, S., and Maga, G. (2005) Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz, Antimicrob. Agents Chemother. 49, 342-349.
55. Robbins, G. K., De Gruttola, V., Shafer, R. W., Smeaton, L. M., Snyder, S. W., Pettinelli, C., Dube, M. P., Fischl, M. A., Pollard, R. B., Delapenha, R., Gedeon, L., van der Horst, C., Murphy, R. L., Becker, M. I., D'Aquila, R. T., Vella, S., Merigan, T. C., and Hirsch, M. S. (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection, N. Engl. J. Med. 349, 2293-2303.
56. Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., Toole, J. J., and Cheng, A. K. (2006) Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV, N. Engl. J. Med. 354, 251-260.